Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2011

Open Access 01-12-2011 | Research article

FGFR4 Gly388Arg polymorphism contributes to prostate cancer development and progression: A meta-analysis of 2618 cases and 2305 controls

Authors: Bin Xu, Na Tong, Shu Q Chen, Li X Hua, Zeng J Wang, Zheng D Zhang, Ming Chen

Published in: BMC Cancer | Issue 1/2011

Login to get access

Abstract

Background

Fibroblast growth factor receptor 4 (FGFR4) displays multiple biological activities, including mitogenic and angiogenic activity, and plays important roles in the etiology and progression of prostate cancer. Gly388Arg polymorphism in FGFR4 gene has been reported to be involved in prostate cancer incidence and aggressiveness in several studies. To derive a more precise estimation of the relationship, a meta-analysis was performed.

Methods

Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated to assess the association.

Results

The Arg388 allele increased prostate cancer risk compared with Gly388 allele (OR = 1.17, 95% CI = 1.07-1.29). When stratified by race, there was a significantly increased prostate cancer risk in Asian and Caucasian populations. Moreover, prostate cancer patients with Arg/Arg genotype had a 1.34-fold increased risk of advanced prostate cancer (95% CI: 1.03-1.74) compared with those with Gly/Gly+Gly/Arg genotype.

Conclusion

This meta-analysis showed the evidence that FGFR4 Gly388Arg polymorphism was associated with an increased risk of prostate cancer development and progression, suggesting that FGFR4 Gly388Arg polymorphism could be a marker for prostate cancer development and progression.
Appendix
Available only for authorised users
Literature
1.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 2009, 59 (4): 225-249. 10.3322/caac.20006.CrossRefPubMed
2.
Wilkie AO, Morriss-Kay GM, Jones EY, Heath JK: Functions of fibroblast growth factors and their receptors. Curr Biol. 1995, 5 (5): 500-507. 10.1016/S0960-9822(95)00102-3.CrossRefPubMed
3.
Powers CJ, McLeskey SW, Wellstein A: Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer. 2000, 7 (3): 165-197. 10.1677/erc.0.0070165.CrossRefPubMed
4.
Sahadevan K, Darby S, Leung HY, Mathers ME, Robson CN, Gnanapragasam VJ: Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer. J Pathol. 2007, 213 (1): 82-90. 10.1002/path.2205.CrossRefPubMed
5.
Gowardhan B, Douglas DA, Mathers ME, McKie AB, McCracken SR, Robson CN, Leung HY: Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer. Br J Cancer. 2005, 92 (2): 320-327.PubMedPubMedCentral
6.
Bange J, Prechtl D, Cheburkin Y, Specht K, Harbeck N, Schmitt M, Knyazeva T, Muller S, Gartner S, Sures I, et al: Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res. 2002, 62 (3): 840-847.PubMed
7.
Morimoto Y, Ozaki T, Ouchida M, Umehara N, Ohata N, Yoshida A, Shimizu K, Inoue H: Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma. Cancer. 2003, 98 (10): 2245-2250. 10.1002/cncr.11778.CrossRefPubMed
8.
FitzGerald LM, Karlins E, Karyadi DM, Kwon EM, Koopmeiners JS, Stanford JL, Ostrander EA: Association of FGFR4 genetic polymorphisms with prostate cancer risk and prognosis. Prostate Cancer Prostatic Dis. 2009, 12 (2): 192-197. 10.1038/pcan.2008.46.CrossRefPubMed
9.
Ho CK, Anwar S, Nanda J, Habib FK: FGFR4 Gly(388)Arg polymorphism and prostate cancer risk in Scottish men. Prostate Cancer Prostatic Dis. 2009
10.
Ma Z, Tsuchiya N, Yuasa T, Inoue T, Kumazawa T, Narita S, Horikawa Y, Tsuruta H, Obara T, Saito M, et al: Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population. Int J Cancer. 2008, 123 (11): 2574-2579. 10.1002/ijc.23578.CrossRefPubMed
11.
Wang J, Stockton DW, Ittmann M: The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression. Clin Cancer Res. 2004, 10 (18 Pt 1): 6169-6178. 10.1158/1078-0432.CCR-04-0408.CrossRefPubMed
12.
Wang J, Yu W, Cai Y, Ren C, Ittmann MM: Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression. Neoplasia. 2008, 10 (8): 847-856.CrossRefPubMedPubMedCentral
13.
Lau J, Ioannidis JP, Schmid CH: Quantitative synthesis in systematic reviews. Ann Intern Med. 1997, 127 (9): 820-826.CrossRefPubMed
14.
DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials. 1986, 7 (3): 177-188. 10.1016/0197-2456(86)90046-2.CrossRefPubMed
15.
Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959, 22 (4): 719-748.PubMed
16.
Begg CB, Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994, 50 (4): 1088-1101. 10.2307/2533446.CrossRefPubMed
17.
18.
Spinola M, Leoni V, Pignatiello C, Conti B, Ravagnani F, Pastorino U, Dragani TA: Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients. J Clin Oncol. 2005, 23 (29): 7307-7311. 10.1200/JCO.2005.17.350.CrossRefPubMed
19.
Dorkin TJ, Robinson MC, Marsh C, Bjartell A, Neal DE, Leung HY: FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease. Oncogene. 1999, 18 (17): 2755-2761. 10.1038/sj.onc.1202624.CrossRefPubMed
20.
Heer R, Douglas D, Mathers ME, Robson CN, Leung HY: Fibroblast growth factor 17 is over-expressed in human prostate cancer. J Pathol. 2004, 204 (5): 578-586. 10.1002/path.1668.CrossRefPubMed
21.
Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, Ornitz DM: Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem. 2006, 281 (23): 15694-15700. 10.1074/jbc.M601252200.CrossRefPubMedPubMedCentral
22.
Desnoyers LR, Pai R, Ferrando RE, Hotzel K, Le T, Ross J, Carano R, D'Souza A, Qing J, Mohtashemi I, et al: Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene. 2008, 27 (1): 85-97. 10.1038/sj.onc.1210623.CrossRefPubMed
23.
Bai JL, Zheng MH, Xia X, Ter-Minassian M, Chen YP, Chen F: MTHFR C677T polymorphism contributes to prostate cancer risk among Caucasians: A meta-analysis of 3511 cases and 2762 controls. Eur J Cancer. 2009, 45 (8): 1443-1449. 10.1016/j.ejca.2009.01.020.CrossRefPubMed
Metadata
Title
FGFR4 Gly388Arg polymorphism contributes to prostate cancer development and progression: A meta-analysis of 2618 cases and 2305 controls
Authors
Bin Xu
Na Tong
Shu Q Chen
Li X Hua
Zeng J Wang
Zheng D Zhang
Ming Chen
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2011
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-11-84

Other articles of this Issue 1/2011

BMC Cancer 1/2011 Go to the issue

Research article

A cyclopalladated complex interacts with mitochondrial membrane thiol-groups and induces the apoptotic intrinsic pathway in murine and cisplatin-resistant human tumor cells

Research article

The extramural metastasis might be categorized in lymph node staging for colorectal cancer

Research article

Methylenetetrahydrofolate reductase polymorphisms and interaction with smoking and alcohol consumption in lung cancer risk: a case-control study in a Japanese population

Research article

Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines

Research article

A short-term in vivo model for giant cell tumor of bone

Research article

Adaptation to HIF-1 deficiency by upregulation of the AMP/ATP ratio and phosphofructokinase activation in hepatomas
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits